07:08 AM EDT, 10/02/2024 (MT Newswires) -- Vera Therapeutics ( VERA ) said Wednesday that it would expand the development of its lead asset, atacicept, following positive results from the ongoing phase 2 and 3 trials in patients with IgA nephropathy and other autoimmune kidney indications.

The company said it plans to initiate a study in Q4 to give its ongoing phase 2 and 3 trials participants extended access to atacicept before it becomes commercially available, allowing for the collection of longer-term data.

It added that in 2025, the company plans to launch a study to assess atacicept's efficacy and safety in expanded IgAN populations, including adults with varying levels of kidney function and adolescents at high risk of progression.

The study will also extend to autoimmune glomerular diseases like primary membranous nephropathy and focal segmental glomerulosclerosis.

Price: 44.20, Change: +1.37, Percent Change: +3.20